F.D.A. Approves 2 Sickle Cell Treatments, One Using CRISPR Gene Editingnews2023-12-09T02:22:13+00:00December 9th, 2023|The New York Times|
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Mostnews2023-12-08T22:46:17+00:00December 8th, 2023|The New York Times|
Why We’re Stuck in a Constant Cycle of Drug Shortagesnews2023-12-06T14:05:41+00:00December 6th, 2023|The New York Times|
¿Un medicamento para que tu perro viva más?news2023-11-30T12:44:11+00:00November 30th, 2023|The New York Times|
Could Longevity Drugs for Dogs Extend Your Pet’s Life?news2023-11-28T05:01:45+00:00November 28th, 2023|The New York Times|
Amazon to Stop Selling Seven Eyedrops After F.D.A. Warningnews2023-11-15T16:16:27+00:00November 15th, 2023|The New York Times|
F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With Wegovynews2023-11-09T01:02:09+00:00November 9th, 2023|The New York Times|
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patientsnews2023-10-31T21:21:11+00:00October 31st, 2023|The New York Times|
F.D.A. Experts Will Vote on Safety of a Cure for Sickle Cell Diseasenews2023-10-30T20:19:43+00:00October 30th, 2023|The New York Times|
Eyedrops From Major Brands May Cause Infection, F.D.A. Saysnews2023-10-29T23:47:48+00:00October 29th, 2023|The New York Times|
